<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vinorelbine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vinorelbine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vinorelbine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10046" href="/d/html/10046.html" rel="external">see "Vinorelbine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11144" href="/d/html/11144.html" rel="external">see "Vinorelbine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708855"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Severe myelosuppression resulting in serious infection, septic shock, hospitalization, and death can occur. Decrease the dose or withhold vinorelbine in accord with recommended dose modifications.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F234356"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Navelbine [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1042325"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Antimicrotubular</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Vinca Alkaloid</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812562"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing may be based on either BSA (mg/m<sup>2</sup>) or weight (mg/<b>kg</b>); use extra precautions to verify dosing parameters during calculations. Protocol-specific details concerning dosing, frequency, and combination regimens should be consulted.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="55d4dc17-731a-495d-a3f9-56649cfd7f09">Hodgkin lymphoma, refractory or recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, refractory or recurrent:</b> Limited data available; dosing regimens and combinations variable: Children ≥10 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">GV regimen: IV: 25 mg/m<sup>2</sup> on days 1 and 8 of a 21-day cycle in combination with gemcitabine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19224841']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19224841'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">GVD regimen: IV: 20 mg/m<sup>2</sup> on day 1 and 8 of a 21-day cycle in combination with gemcitabine and pegylated liposomal doxorubicin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25862234']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25862234'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IVB regimen: IV: 25 mg/m<sup>2</sup> on days 1 and 5 of a 21-day cycle in combination with ifosfamide and bortezomib (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25833390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25833390'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="71d5403a-e655-4441-8b71-fb79784ecd86">Leukemias, refractory or recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leukemias (acute ALL, AML), refractory or recurrent:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">TVTC regimen:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IV: 0.67 mg/<b>kg</b> once weekly on days 0, 7, 14 of a 14-day cycle in combination with topotecan, clofarabine, and thiotepa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20205253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20205253'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: IV: 20 mg/m<sup>2</sup> once weekly on days 0, 7, and 14 of a 14-day cycle in combination with topotecan, clofarabine, and thiotepa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24115731','lexi-content-ref-20205253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24115731','lexi-content-ref-20205253'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">BDMV regimen: Infants ≥9 months, Children, and Adolescents: IV: 25 mg/m<sup>2</sup> on days 3, 10, and 17 in combination with bortezomib, dexamethasone, and mitoxantrone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27352191']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27352191'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c4a04e84-086d-4b16-93f7-8518e335b454">Solid tumors, refractory or recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid tumors, refractory or recurrent:</b> Limited data available: Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Monotherapy:</i> IV: 30 mg/m<sup>2</sup> once weekly for weeks 1 to 6 of an 8-week cycle for 10 courses; may reduce dosage to 27 mg/m<sup>2</sup> for Grade 3 or 4 hematologic toxicity in patients who demonstrate objective response or who have had treatment delay beyond 63 days (week 9) from the previous course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19533657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19533657'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy:</i> IV: 25 mg/m<sup>2</sup> on days 1, 8, and 15 of each 28-day cycle in combination with cyclophosphamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15378498','lexi-content-ref-22633624']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15378498','lexi-content-ref-22633624'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity: </b>The presented dosing adjustments are based on experience in adult patients. Refer to specific protocol for management in pediatric patients if available.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult: <b>Note:</b> In patients with concurrent hematologic toxicity and hepatic impairment, administer the lower of the doses determined from the adjustment recommendations.</p>
<p style="text-indent:-2em;margin-left:6em;">Neutrophil counts should be ≥1,000 cells/mm<sup>3</sup> prior to the administration of vinorelbine. Adjustments in the dosage of vinorelbine should be based on neutrophil counts obtained on the day of treatment as follows:</p>
<p style="text-indent:-2em;margin-left:8em;">Neutrophils ≥1,500 cells/mm<sup>3</sup> on day of treatment: Administer 100% of starting dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Neutrophils 1,000 to 1,499 cells/mm<sup>3</sup> on day of treatment: Administer 50% of starting dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Neutrophils &lt;1,000 cells/mm<sup>3</sup> on day of treatment: Do not administer. Repeat neutrophil count in 1 week; if 3 consecutive doses are held because neutrophil count is &lt;1,000 cells/mm<sup>3</sup>, discontinue vinorelbine.</p>
<p style="text-indent:-2em;margin-left:6em;">For patients who, during treatment, have experienced fever and/or sepsis while neutropenic or had 2 consecutive weekly doses held due to neutropenia, subsequent doses of vinorelbine should be:</p>
<p style="text-indent:-2em;margin-left:8em;">Neutrophils ≥1,500 cells/mm<sup>3</sup>: Administer 75% of starting dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Neutrophils 1,000 to 1,499 cells/mm<sup>3</sup> on day of treatment: Administer 37.5% of starting dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Neutrophils &lt;1,000 cells/mm<sup>3</sup> on day of treatment: Do not administer. Repeat neutrophil count in 1 week.</p>
<p style="text-indent:-2em;margin-left:6em;">Neurotoxicity (peripheral neuropathy or autonomic neuropathy causing constipation) ≥ grade 2: Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe adverse events: Reduce dose or discontinue treatment.</p></div>
<div class="block dorp drugH1Div" id="F52729864"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; consult individual protocols. Based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F52729865"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">All patients: <b>Note:</b> In patients with concurrent hematologic toxicity and hepatic impairment, administer the lower of the doses determined from the adjustment recommendations. Administer with caution in patients with hepatic insufficiency. In patients who develop hyperbilirubinemia during treatment with vinorelbine, the dose should be adjusted for total bilirubin as follows:</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin ≤2 mg/dL: Administer 100% of dose</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin 2.1 to 3 mg/dL: Administer 50% of dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16131047','lexi-content-ref-16473644','lexi-content-ref-17914077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16131047','lexi-content-ref-16473644','lexi-content-ref-17914077'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin &gt;3 mg/dL: Administer 25% of dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16131047','lexi-content-ref-16473644','lexi-content-ref-17914077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16131047','lexi-content-ref-16473644','lexi-content-ref-17914077'])">Ref</a></span>)</p></div>
<div class="block doa drugH1Div" id="F234361"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10046" href="/d/html/10046.html" rel="external">see "Vinorelbine: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Begin a prophylactic bowel regimen (including adequate dietary fiber intake, hydration, and routine stool softeners) to minimize potential constipation, bowel obstruction, and/or paralytic ileus. Do not administer if ANC &lt;1,000/mm<sup>3</sup>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b8423721-7a23-4fed-bf36-91a0c75f98e6">Breast cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, metastatic (off-label use):</b>
<b>IV:</b> 25 mg/m<sup>2</sup> every 7 days (as a single agent) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11745280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11745280'])">Ref</a></span>) <b>or</b> 30 mg/m<sup>2</sup> every 7 days (as a single agent); after 13 weeks, may change dosing interval to every 14 days (for patient convenience), continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10370781']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10370781'])">Ref</a></span>) <b>or</b> 25 mg/m<sup>2</sup> every 7 days (in combination with trastuzumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17614302','lexi-content-ref-11352965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17614302','lexi-content-ref-11352965'])">Ref</a></span>) <b>or</b> 30 or 35 mg/m<sup>2</sup> days 1 and 8 every 21 days (in combination with trastuzumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21149659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21149659'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5a4717b7-7018-4db7-91b6-7467d949c9f0">Cervical cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cervical cancer (off-label use):</b>
<b>IV:</b> 30 mg/m<sup>2</sup> days 1 and 8 of a 21-day treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14766259','lexi-content-ref-15589588']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14766259','lexi-content-ref-15589588'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4ebbaa33-8ab0-44b8-a662-fd68c7d18267">Hodgkin lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, relapsed or refractory (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>GVD regimen:</i>
<b>IV:</b> 20 mg/m<sup>2</sup> (15 mg/m<sup>2</sup> if post transplant) on days 1 and 8 of a 21-day cycle (in combination with gemcitabine and doxorubicin liposomal) for 2 to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17426059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17426059'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>IGEV regimen:</i>
<b>IV: </b>20 mg/m<sup>2</sup> on day 1 of a 21-day cycle (in combination with ifosfamide, mesna, gemcitabine, and prednisolone) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17229633']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17229633'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b00a027-bd66-4d8a-903c-6d47086c0533">Malignant pleural mesothelioma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant pleural mesothelioma (off-label use):</b>
<b>IV:</b> 30 mg/m<sup>2</sup> (maximum dose: 60 mg) once weekly for 6 doses (each cycle consists of 6 once-weekly doses), continue until disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18486273','lexi-content-ref-11099320']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18486273','lexi-content-ref-11099320'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c818fdd2-0859-4362-9aae-976c7de99cda">Non–small cell lung cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Metastatic (single-agent therapy):</i>
<b>IV: </b>30 mg/m<sup>2</sup> once a week.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Locally advanced or metastatic (in combination with cisplatin):</i>
<b>IV: </b>25 mg/m<sup>2</sup> on days 1, 8, 15, and 22 of a 28-day cycle <b>or</b> 30 mg/m<sup>2</sup> once a week.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Advanced disease (off-label dosing):</i>
<b>IV: </b>25 to 30 mg/m<sup>2</sup> days 1, 8, and 15 every 28 days (in combination with gemcitabine) for 6 cycles <b>or</b> until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17922972','lexi-content-ref-12124835']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17922972','lexi-content-ref-12124835'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="284232a0-76e4-4800-a7c4-0fb40411e474">Ovarian cancer, relapsed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, relapsed (off-label use):</b>
<b>IV:</b> 25 mg/m<sup>2</sup> every 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8823334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8823334'])">Ref</a></span>) <b>or</b> 30 mg/m<sup>2</sup> days 1 and 8 of a 21-day treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15581954']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15581954'])">Ref</a></span>) until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5428a25a-234b-4857-ba4a-cff968b8a394">Salivary gland cancer, recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Salivary gland cancer, recurrent (off-label use):</b>
<b>IV:</b> 25 mg/m<sup>2</sup> on days 1 and 8 of a 21-day cycle (in combination with cisplatin) for a minimum of 3 cycles and for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11169936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11169936'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c44ba3ae-9b89-4ba0-8466-3b197de98c07">Small cell lung cancer, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small cell lung cancer, refractory (off-label use):</b>
<b>IV:</b> 25 or 30 mg/m<sup>2</sup> every 7 days until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8604245','lexi-content-ref-8398301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8604245','lexi-content-ref-8398301'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7010e3ba-7b4f-4a1f-86d7-7a0447b9278e">Soft tissue sarcoma, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Soft tissue sarcoma, advanced (off-label use):</b>
<b>IV:</b> 25 mg/m<sup>2</sup> days 1 and 8 of a 21-day treatment cycle (in combination with gemcitabine) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17385194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17385194'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992081"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling; however, no dosage adjustment is necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: No need for dosage adjustment is expected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>); however, some sources suggest reducing the dose as well as administering either after dialysis (on dialysis days) or on nondialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20118214','lexi-content-ref-29209521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20118214','lexi-content-ref-29209521'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989279"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> In patients with concurrent hematologic toxicity and hepatic impairment, administer the lower of the doses determined from the adjustment recommendations.</p>
<p style="text-indent:-2em;margin-left:2em;">Use with caution in patients with hepatic impairment. In patients with hepatic impairment or who develop hyperbilirubinemia during treatment with vinorelbine, adjust dose for total bilirubin as follows:</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin ≤2 mg/dL: Administer 100% of vinorelbine dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin 2.1 to 3 mg/dL: Administer 50% of vinorelbine dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16131047','lexi-content-ref-16473644','lexi-content-ref-17914077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16131047','lexi-content-ref-16473644','lexi-content-ref-17914077'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin &gt;3 mg/dL: Administer 25% of vinorelbine dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16131047','lexi-content-ref-16473644','lexi-content-ref-17914077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16131047','lexi-content-ref-16473644','lexi-content-ref-17914077'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Patients (breast cancer) with extensive liver metastases (&gt;75% of liver volume): Administer 50% of vinorelbine dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16131047','lexi-content-ref-17914077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16131047','lexi-content-ref-17914077'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F234327"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Neurotoxicity (44%), peripheral neuropathy (20%; grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (12% to 30%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (≤34%), vomiting (≤31%), constipation (29%), diarrhea (12% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (80% to 85%; grades 3/4: 29% to 69%), leukopenia (81% to 83%; grades 3/4: 12% to 32%), anemia (77%; grades 3/4: 1% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase (54%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (22% to 38%; includes erythema at injection site, vein discoloration), pain at injection site (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Localized phlebitis (10%), chest pain (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Neuropathy (grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (≤8%), thrombocytopenia (3% to 4%; grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (≤8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Ototoxicity (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Intestinal necrosis, intestinal obstruction, intestinal perforation, paralytic ileus</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow depression</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pulmonary disease, pulmonary toxicity (including acute respiratory distress syndrome, interstitial pneumonitis, severe acute bronchospasm)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal pain, abnormal gait, anaphylaxis, angioedema, arthralgia, auditory impairment, back pain, decreased deep tendon reflex, deep vein thrombosis, dermatitis, dysphagia, electrolyte disorder, esophagitis, exfoliation of skin, flushing, headache, hemorrhagic cystitis, hypertension, hyponatremia, hypotension, jaw pain, localized rash, mucositis, myalgia, myasthenia, myocardial infarction, palmar-plantar erythrodysesthesia, pancreatitis, pneumonia, pruritus, pulmonary edema, pulmonary embolism, radiation recall phenomenon, SIADH, skin blister, skin rash, tachycardia, tumor pain, urticaria, urticaria at injection site, vasodilation, vestibular disturbance</p></div>
<div class="block coi drugH1Div" id="F234341"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer’s US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to vinorelbine or any component of the formulation; drug-induced severe granulocytopenia or severe thrombocytopenia.</p></div>
<div class="block war drugH1Div" id="F234324"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Severe myelosuppression resulting in serious infection, septic shock, hospitalization, and death may occur. Neutropenia, thrombocytopenia, and anemia may occur with vinorelbine (either as a single agent or in combination with other chemotherapy); neutropenia is the major dose-limiting toxicity (grade 3 or 4 neutropenia has commonly occurred). Neutropenia has resulted in hospitalization (for fever) and/or sepsis. The neutrophil nadir occurs between 7 to 10 days after administration, and recovery occurs within the following 7 to 14 days.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant; ensure proper catheter or needle position prior to (and during) infusion. Avoid extravasation. Extravasation may cause local tissue necrosis and/or thrombophlebitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation may occur with vinorelbine. Begin a prophylactic bowel regimen (including adequate dietary fiber intake, hydration, and routine stool softeners) to minimize potential constipation, bowel obstruction and/or paralytic ileus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Drug-induced liver injury (transaminase and bilirubin elevations) may occur in patients receiving vinorelbine (either as a single-agent or in combination with other chemotherapy). Vinorelbine elimination is predominantly hepatic; use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropathy: Sensory and motor neuropathies may occur in patients receiving vinorelbine; may be severe. Signs/symptoms of neuropathy include paresthesia, hyperesthesia, hyporeflexia, and muscle weakness.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Pulmonary toxicity, including severe acute bronchospasm, interstitial pneumonitis, and/or acute respiratory distress syndrome (ARDS) may occur with vinorelbine; fatalities due to interstitial pneumonitis and ARDS have occurred. The mean time to onset of interstitial pneumonitis and ARDS was 1 week (range: 3 to 8 days).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• For IV use only: <b>Vinorelbine is for IV administration only. Administration of other vinca alkaloids by other routes has been fatal.</b> The Institute for Safe Medication Practices (ISMP) strongly recommends dispensing vinca alkaloids in a minibag (<b>NOT</b> a syringe) (ISMP 2020). Vinorelbine should <b>NOT</b> be prepared during the preparation of any intrathecal medications. After preparation, keep vinorelbine in a location away from the separate storage location recommended for intrathecal medications (ASCO/ONS [Neuss 2016]).</p></div>
<div class="block foc drugH1Div" id="F234335"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/5 mL (5 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Navelbine: 10 mg/mL (1 mL [DSC]); 50 mg/5 mL (5 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (1 mL); 50 mg/5 mL (5 mL)</p></div>
<div class="block geq drugH1Div" id="F234320"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16324098"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Vinorelbine Tartrate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $21.60 - $90.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/5 mL (per mL): $21.60 - $90.29</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868609"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (1 mL, 5 mL)</p></div>
<div class="block admp drugH1Div" id="F52614011"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: <b>For IV use only; FATAL IF GIVEN INTRATHECALLY.</b> Administer as a direct intravenous push or rapid bolus over 6 to 10 minutes (up to 30 minutes); in pediatric trials, vinorelbine was typically administered over 6 to 10 minutes; use of a side port of a free-flowing IV line is suggested. Longer infusions may increase the risk of pain and phlebitis. Intravenous doses should be followed by at least 75 to 125 mL of NS or D5W to reduce the incidence of phlebitis and inflammation.</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant; avoid extravasation. Assure proper needle or catheter position prior to administration. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (See Management of Drug Extravasations for more details); apply dry warm compresses for 20 minutes 4 times a day for 1 to 2 days; elevate extremity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>). Remaining portion of the vinorelbine dose should be infused through a separate vein.</p></div>
<div class="block adm drugH1Div" id="F234338"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b>
<b>For IV use only; fatal if given by other routes.</b> Administer over 6 to 10 minutes (the manufacturer recommends infusing into the side port of a free-flowing IV line); follow the infusion with at least 75 to 125 mL of a compatible solution to reduce the incidence of phlebitis and inflammation.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Vesicant; ensure proper needle or catheter position prior to administration. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote; remove needle/cannula; apply dry warm compresses for 20 minutes 4 times a day for 1 to 2 days; elevate extremity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>). Remaining portion of the vinorelbine dose should be infused through a separate vein.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hyaluronidase:</i> If needle/cannula still in place, administer 1 to 6 mL hyaluronidase (150 units/mL) into the existing IV line; the usual dose is 1 mL hyaluronidase for each 1 mL of extravasated drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449','lexi-content-ref-21255716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449','lexi-content-ref-21255716'])">Ref</a></span>). If needle/cannula was removed, inject 1 to 6 mL (150 units/mL) subcutaneously in a clockwise manner using 1 mL for each 1 mL of drug extravasated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21255716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21255716'])">Ref</a></span>) <b>or</b> administer 1 mL (150 units/mL) as 5 separate 0.2 mL injections (using a 25-gauge needle) subcutaneously into the extravasation site (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Polovich.2009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Polovich.2009'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49132725"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F234350"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 2°C to 8°C (36°F to 46°F); do not freeze. Protect from light. Intact (unopened) vials are stable at 25°C (77°F) for up to 72 hours. Solutions diluted for infusion in polyvinyl chloride bags (D5W, NS, <sup>1</sup>/<sub>2</sub>NS, D5<sup>1</sup>/<sub>2</sub>NS, LR, or Ringer's) are stable for up to 24 hours at 5°C to 30°C (41°F to 86°F) under normal room light. After preparation, keep vinorelbine in a location <b>away</b> from the separate storage location recommended for intrathecal medications (Jacobson 2009).</p></div>
<div class="block usep drugH1Div" id="F53569480"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of non-small cell lung cancer (FDA approved in adults); has also been used for refractory/recurrent solid tumors, Hodgkin lymphoma, and leukemias.</p></div>
<div class="block mst drugH1Div" id="F234403"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Vinorelbine may be confused with vinBLAStine, vinCRIStine</p>
<p style="text-indent:-2em;margin-left:4em;">Vinorelbine (50 mg/5 mL; Hospira manufacturer) may be confused with conventional cytarabine (100 mg/5 mL; Hospira manufacturer) due to similar packaging; potential for inadvertent intrathecal administration of vinorelbine may occur (ISMP [Smetzer 2015]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Vinorelbine is for <b>IV administration only</b>: Inadvertent intrathecal administration of other vinca alkaloids has resulted in death. The ISMP strongly recommends dispensing vinca alkaloids in a minibag, and <b>NOT</b> a syringe (ISMP 2020). Vinorelbine should NOT be prepared during the preparation of any intrathecal medications. After preparation, keep vinorelbine in a location away from the separate storage location recommended for intrathecal medications</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F234388"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F234329"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CISplatin: May enhance the adverse/toxic effect of Vinorelbine. Specifically, the combination may be associated with a higher risk of granulocytopenia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Vinorelbine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Vinorelbine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: May enhance the neutropenic effect of Vinorelbine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MitoMYcin (Systemic): Antineoplastic Agents (Vinca Alkaloids) may enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): May enhance the adverse/toxic effect of Vinorelbine. Specifically hematologic toxicity may be increased. PACLitaxel (Conventional) may enhance the neurotoxic effect of Vinorelbine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): May enhance the adverse/toxic effect of Vinorelbine. Specifically hematologic toxicity may be increased. PACLitaxel (Protein Bound) may enhance the neurotoxic effect of Vinorelbine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53145265"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who could become pregnant should use effective contraception during vinorelbine treatment and for 6 months after the final vinorelbine dose. Patients with partners who could become pregnant should use effective contraception during treatment and for 3 months following the last vinorelbine dose.</p>
<p style="text-indent:0em;margin-top:2em;">Vinorelbine may damage spermatozoa and may cause decreased fertility in male patients.</p></div>
<div class="block pri drugH1Div" id="F5720023"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism and on findings in animal reproduction studies, vinorelbine may cause fetal harm if administered during pregnancy.</p></div>
<div class="block mopp drugH1Div" id="F53569481"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential and platelet count (prior to each dose, and after treatment), hepatic function tests; monitor for new-onset pulmonary symptoms (or worsening from baseline); monitor for neuropathy (new or worsening symptoms; monitor infusion site; monitor for signs symptoms of constipation/ileus.</p></div>
<div class="block pha drugH1Div" id="F234323"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Vinorelbine is a semisynthetic vinca alkaloid which binds to tubulin and inhibits microtubule formation, therefore, arresting the cell at metaphase by disrupting the formation of the mitotic spindle; it is specific for the M and S phases. Vinorelbine may also interfere with nucleic acid and protein synthesis by blocking glutamic acid utilization.</p></div>
<div class="block phk drugH1Div" id="F234340"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: binds extensively to human platelets and lymphocytes (80% to 91%)</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 2 to 17 years: 21.1 ± 12.2 L/kg (Johansen 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 25 to 40 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 80% to 91%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic, via CYP3A4, to two metabolites, deacetylvinorelbine (active) and vinorelbine N-oxide</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Triphasic:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 2 to 17 years: Terminal: 16.5 ± 9.7 hours (Johansen 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Terminal: ~28 to 44 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~46%); urine (~18%, 10% to 12% as unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F234343"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Navelbine</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fada vinorelbina | Neocitec | Vinorel | Vinorelbina kemex | Vinorgen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Eberelbin | Navelbine | Vinorelbin accord | Vinorelbin actavis | Vinorelbin Medac | Vinorelbin sandoz</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">As Vinorelbine | Navelbine | Vinorelbine Kabi | Vinorelbine Link | Vinorelbine tart</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinorelbin actavis | Vinorelbine accord | Vinorelbine ebewe | Vinorelbine teva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Navelbin | Vinorelbin actavis | Vinorelbin ebewe</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Evotabina | Navelbine | Neocitec | Tevavinor | Vilne</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinorelbin actavis | Vinorelbin Cancernova | Vinorelbin ebewe | Vinorelbin sandoz | Vinorelbin teva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Navelbine</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai ke qing | Vinorelbine | Vinorelbine ditartrate</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Fada vinorelbina | Labdosa vilne | Navelbine | Vinobina | Vinorel | Vinorelbina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Navelbin | Navirel | Nibrevin | Vinorelbine accord | Vinorelbine glenmark</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bendarelbin | Eurovinorelbin | Navelbine | Navin | Navirel | Riborelbin | Vinorelbin | Vinorelbin accord | Vinorelbin actavis | Vinorelbin aurobindo | Vinorelbin axios | Vinorelbin cell pharm | Vinorelbin haemato | Vinorelbin hexal | Vinorelbin NC | Vinorelbin Omnicare | Vinorelbin oncotrade | Vinorelbin Onkovis | Vinorelbin phares | Vinorelbin vitane</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinelbine</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Vinorelbina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinorelbin accord | Vinorelbin ebewe</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinorelbin ebewe | Vinorelbina aurovitas | Vinorelbine | Vinorelbine actavis</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Eunades | Navelbine | Vinorelbina accord | Vinorelbina Actavis | Vinorelbina Ferrer Farma | Vinorelbina Glenmark | Vinorelbina Ips | Vinorelbina sandoz</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Navirel | Vinorelbin actavis | Vinorelbin Bmm Pharma | Vinorelbine accord | Vinorelbine orifarm</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinorelbine accord | Vinorelbine actavis | Vinorelbine Dci | Vinorelbine ebewe | Vinorelbine Mylan | Vinorelbine pierre fabre | Vinorelbine sandoz</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinorelbine</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinorelbin/ebewe | Zaolin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinorelbin ebewe | Vinorelbine</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Navelbin | Neocitec | Vinorelbine Polpharma</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Relubin | Vinorelbine | Vinorelsin | Vinorkal</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinorelbine</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Navelbine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinbicel | Vinbine</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Eunades | Navelbine | Vinorelbina | Vinorelbina accord | Vinorelbina Actavis | Vinorelbina doc | Vinorelbina HOS</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Navelbine</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Rozeus</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Pfizer vinorelbine | Vinolbin | Vinorelbine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Navelbine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Eberelbin | Navelbine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinorelbin | Vinorelbine accord</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cipla vinorelbine | Navelbine | Vinorelbin accord | Vinorelbin ebewe | Vinorelbine actavis</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Navelbine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bagovir | Navelbine | Setroxin | Vanevin | Viessia | Vincanorel | Vinilex</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">DBL Vinorelbine | Navelbine | Vinelbine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Navirel | Vinorelbine accord | Vinorelbine actavis | Vinorelbine allgen | Vinorelbine ebewe | Vinorelbine pch</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Navirel | Vinorelbin | Vinorelbin accord | Vinorelbin Bmm Pharma | Vinorelbin mayne | Vinorelbin meda | Vinorelbine orifarm</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Sagent vinorelbine | Vinorelbine</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Eunexon</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinotel</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Navalbine | Navelbine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Navirel | Neocitec | Vinorelbin ebewe | Vinorelbine accord | Vinorelbine Alvogen | Vinorelbine Polpharma</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinorelbine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Navirel | Vinorelbina | Vinorrelbin | Vinorrelbina accord | Vinorrelbina Actavis | Vinorrelbina Sandoz</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinorelbina sandoz</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Navelbine</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinorelbin | Vinorelbin actavis | Vinorelbin ebewe | Vinorelbina accord | Vinorelbina alvogen | Vinorelbine</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cituvin | Firelbin | Maverex | Navelbine | Velbin | Vincatera | Vinelbine | Vinorelbine | Vinorelbine kelun kazfarm | Vinorelbine medac | Vinorelbine teva</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Navelbine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinorelbin actavis | Vinorelbin ebewe | Vinorelbin hospira | Vinorelbine accord | Vinorelbine orifarm</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Vinorelbine dbl</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Vinorelbin accord | Vinorelbin caduceus | Vinorelbin ebewe</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Navelbin | Navirel | Vinorelbin Hikma | Vinorelbin sandoz | Vinorelbine glenmark | Vinorelbine Hikma | Visera</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">DBL Vinorelbine | Navelbine | Viessia</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cytorelbine | Navelbine | Vinorel | Vinorelbine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Renovel | Vinalbin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Vinelbine | Vinobin | Vinorelbine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Navelbine | Navelik | Navirel | Oncobine | Velbimeda | Vinelbin | Vinorelbine ebewe | Vinorelbine teva</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Filcrin | Navelbine | Vinorelbina | Vinorelbina FU</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspen Vinorelbin | Carcyt | Cipla vinorelbine | Eurovin | Navelbine | Teva Vinorelbine | Vinorel | Vinorelbin ebewe | Vinorelbine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11169936">
<a name="11169936"></a>Airoldi M, Pedani F, Succo G, et al, “Phase II Randomized Trial Comparing Vinorelbine versus Vinorelbine Plus Cisplatin in Patients With Recurrent Salivary Gland Malignancies,” <i>Cancer</i>, 2001, 91(3):541-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/11169936/pubmed" id="11169936" target="_blank">11169936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21149659">
<a name="21149659"></a>Andersson M, Lidbrink E, Bjerre K, et al, “Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab as First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The HERNATA Study,” <i>J Clin Oncol</i>, 2011, 29(3):264-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/21149659/pubmed" id="21149659" target="_blank">21149659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8823334">
<a name="8823334"></a>Bajetta E, Di Leo A, Biganzoli L, et al, “Phase II Study of Vinorelbine in Patients With Pretreated Advanced Ovarian Cancer: Activity in Platinum-Resistant Disease,” <i>J Clin Oncol</i>, 1996, 14(9):2546-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/8823334/pubmed" id="8823334" target="_blank">8823334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17426059">
<a name="17426059"></a>Bartlett NL, Niedzwiecki D, Johnson JL, et al, "Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin (GVD), a Salvage Regimen in Relapsed Hodgkin's Lymphoma: CALGB 59804," <i>Ann Oncol</i>, 2007, 18(6):1071-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/17426059/pubmed" id="17426059" target="_blank">17426059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17614302">
<a name="17614302"></a>Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab Plus Vinorelbine or Taxane Chemotherapy for HER2-Overexpressing Metastatic Breast Cancer: The Trastuzumab and Vinorelbine or Taxane Study. <i>Cancer</i>. 2007;110(5):965-972.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/17614302/pubmed" id="17614302" target="_blank">17614302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11352965">
<a name="11352965"></a>Burstein HJ, Kuter I, Campos SM, et al, "Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer," <i>J Clin Oncol</i>, 2001, 19(10):2722-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/11352965/pubmed" id="11352965" target="_blank">11352965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15378498">
<a name="15378498"></a>Casanova M, Ferrari A, Bisogno G, et al, “Vinorelbine and Low-Dose Cyclophosphamide in the Treatment of Pediatric Sarcomas: Pilot Study for the Upcoming European Rhabdomyosarcoma Protocol,” <i>Cancer</i>, 2004, 101(7):1664-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/15378498/pubmed" id="15378498" target="_blank">15378498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12115359">
<a name="12115359"></a>Casanova M, Ferrari A, Spreafico F, et al, “Vinorelbine in Previously Treated Advanced Childhood Sarcomas: Evidence of Activity in Rhabdomyosarcoma,” <i>Cancer</i>, 2002, 94(12):3263-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/12115359/pubmed" id="12115359" target="_blank">12115359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19224841">
<a name="19224841"></a>Cole PD, Schwartz CL, Drachtman RA, et al. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's Disease: a children's oncology group report. <i>J Clin Oncol</i>. 2009;27(9):1456-1461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/19224841/pubmed" id="19224841" target="_blank">19224841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17385194">
<a name="17385194"></a>Dileo P, Morgan JA, Zahrieh D, et al, “Gemcitabine and Vinorelbine Combination Chemotherapy for Patients With Advanced Soft Tissue Sarcomas: results of a phase II trial.” <i>Cancer</i>, 2007, 109(9):1863-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/17385194/pubmed" id="17385194" target="_blank">17385194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16131047">
<a name="16131047"></a>Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. <i>Oncology (Williston Park)</i>. 2005;19(8):1057-1063; discussion 1063-1064, 1069.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/16131047/pubmed" id="16131047" target="_blank">16131047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473644">
<a name="16473644"></a>Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. <i>Semin Oncol</i>. 2006;33(1):50-67. doi:10.1053/j.seminoncol.2005.11.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/16473644/pubmed" id="16473644" target="_blank">16473644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8604245">
<a name="8604245"></a>Furuse K, Kubota K, Kawahara M, et al, “Phase II Study of Vinorelbine in Heavily Previously Treated Small Cell Lung Cancer. Japan Lung Cancer Vinorelbine Study Group,” <i>Oncology</i>, 1996, 53(2):169-172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/8604245/pubmed" id="8604245" target="_blank">8604245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17922972">
<a name="17922972"></a>Greco FA, Spigel DR, Kuzur ME, et al, “Paclitaxel/Carboplatin/Gemcitabine versus Gemcitabine/Vinorelbine in Advanced Non-Small-Cell Lung Cancer: A Phase II/III Study of the Minnie Pearl Cancer Research Network,” <i>Clin Lung Cancer</i>, 2007, 8(8):483-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/17922972/pubmed" id="17922972" target="_blank">17922972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12124835">
<a name="12124835"></a>Herbst RS, Khuri FR, Lu C, et al, “The Novel and Effective Nonplatinum, Nontaxane Combination of Gemcitabine and Vinorelbine in Advanced Nonsmall Cell Lung Carcinoma: Potential for Decreased Toxicity and Combination With Biological Therapy,” <i>Cancer</i>, 2002, 95(2):340-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/12124835/pubmed" id="12124835" target="_blank">12124835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25833390">
<a name="25833390"></a>Horton TM, Drachtman RA, Chen L, et al. A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study. <i>Br J Haematol</i>. 2015;170(1):118-122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/25833390/pubmed" id="25833390" target="_blank">25833390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medicine Practices (ISMP). <i>ISMP Targeted Medication Safety Best Practices for Hospitals</i>. https://www.ismp.org/sites/default/files/attachments/2020-02/2020-2021%20TMSBP-%20FINAL_1.pdf. Published February 21, 2020. Accessed January 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19786650">
<a name="19786650"></a>Jacobson JO, Polovich M, McNiff KK, et al, “American Society of Clinical Oncology/ Oncology Nursing Society Chemotherapy Administration Safety Standards,” <i>J Clin Oncol</i>, 2009, 27(32):5469-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/19786650/pubmed" id="19786650" target="_blank">19786650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25862234">
<a name="25862234"></a>Jaffray M, Buchbinder N, Lutun A, Schneider P, Piquenot JM, Vannier JP. Salvage therapy with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin for relapsed or refractory pediatric Hodgkin lymphoma. Results of a retrospective series of four children. <i>Ann Hematol</i>. 2015;94(8):1401-1406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/25862234/pubmed" id="25862234" target="_blank">25862234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20118214">
<a name="20118214"></a>Janus N, Thariat J, Boulanger H, et al, “Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,” <i>Ann Oncol</i>, 2010, 21(7):1395-403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/20118214/pubmed" id="20118214" target="_blank">20118214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8398301">
<a name="8398301"></a>Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, et al, “Phase II Study of Vinorelbine (Navelbine) in Previously Treated Small Cell Lung Cancer Patients. EORTC Lung Cancer Cooperative Group,” <i>Eur J Cancer</i>, 1993, 29(12):1720-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/8398301/pubmed" id="8398301" target="_blank">8398301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16428494">
<a name="16428494"></a>Johansen M, Kuttesch J, Bleyer WA, Krailo M, Ames M, Madden T. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. <i>Clin Cancer Res</i>. 2006;12(2):5165-5122. doi: 10.1158/1078-0432.CCR-05-1541.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/16428494/pubmed" id="16428494" target="_blank">16428494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29346042">
<a name="29346042"></a>Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2018;36(13):1343-1373. doi:10.1200/JCO.2017.76.6394<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/29346042/pubmed" id="29346042" target="_blank">29346042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19533657">
<a name="19533657"></a>Kuttesch JF, Krailo MD, Madden T, et al. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a children's oncology group study. <i>Pediatr Blood Cancer</i>. 2009;53(4):590-593.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/19533657/pubmed" id="19533657" target="_blank">19533657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8877249">
<a name="8877249"></a>LeVeque D and Jehl F, “Clinical Pharmacokinetics of Vinorelbine,” <i>Clin Pharmacokinet</i>, 1996, 31(3):184-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/8877249/pubmed" id="8877249" target="_blank">8877249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26324367">
<a name="26324367"></a>Masters GA, Temin S, Azzoli CG. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update [published correction appears in <i>J Clin Oncol</i>. 2016;34(11):1287]. <i>J Clin Oncol</i>. 2015;33(30):3488-3515.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/26324367/pubmed" id="26324367" target="_blank">26324367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22633624">
<a name="22633624"></a>Minard-Colin V, Ichante JL, Nguyen L, et al. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma – a report from the Société Française des Cancers et leucémies de l’Enfant et de l’adolescent (SFCE). <i>Eur J Cancer</i>. 2012;48:2409-2416.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/22633624/pubmed" id="22633624" target="_blank">22633624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19720909">
<a name="19720909"></a>Monk BJ, Sill MW, McMeekin DS, et al, "Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study," <i>J Clin Oncol</i>, 2009, 27(28):4649-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/19720909/pubmed" id="19720909" target="_blank">19720909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al, “Management of Uncommon Chemotherapy-Induced Emergencies,” <i>Lancet Oncol</i>, 2011, 12(8):806-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14766259">
<a name="14766259"></a>Muggia FM, Blessing JA, Method M, et al, “Evaluation of Vinorelbine in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study,” <i>Gynecol Oncol</i>, 2004, 92(2):639-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/14766259/pubmed" id="14766259" target="_blank">14766259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15589588">
<a name="15589588"></a>Muggia FM, Blessing JA, Waggoner S, et al, “Evaluation of Vinorelbine in Persistent or Recurrent Nonsquamous Carcinoma of the Cervix: A Gynecologic Oncology Group Study,” <i>Gynecol Oncol</i>, 2005, 96(1):108-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/15589588/pubmed" id="15589588" target="_blank">15589588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Navelbine.1">
<a name="Navelbine.1"></a>Navelbine (vinorelbine) [prescribing information]. Parsippany, NJ: Pierre Fabre Pharmaceuticals Inc; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27868581">
<a name="27868581"></a>Neuss MN, Gilmore TR, Belderson KM, et al. 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology<i>. J Oncol Pract</i>. 2016;12(12):1262-1271. doi:10.1200/JOP.2016.017905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/27868581/pubmed" id="27868581" target="_blank">27868581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29209521">
<a name="29209521"></a>Pedrazzoli P, Silvestris N, Santoro A, et al. Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN). <i>ESMO Open</i>. 2017;2(3):e000167. doi:10.1136/esmoopen-2017-000167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/29209521/pubmed" id="29209521" target="_blank">29209521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al, “Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,” <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Polovich.2009">
<a name="Polovich.2009"></a>Polovich M, Whitford JN and Olsen M, <i>Chemotherapy and Biotherapy Guidelines and Recommendations for Practice</i>, 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20555089">
<a name="20555089"></a>Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/20555089/pubmed" id="20555089" target="_blank">20555089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133. doi: 10.1093/annonc/mdw270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15581954">
<a name="15581954"></a>Rothenberg ML, Liu PY, Wilczynski s, et al, “Phase II Trial of Vinorelbine for Relapsed Ovarian Cancer: A Southwest Oncology Group Study,” <i>Gynecol Oncol</i>, 2004, 95(3):506-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/15581954/pubmed" id="15581954" target="_blank">15581954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17229633">
<a name="17229633"></a>Santoro A, Magagnoli M, Spina M, et al, “Ifosfamide, Gemcitabine, and Vinorelbine: A New Induction Regimen for Refractory and Relapsed Hodgkin's Lymphoma,” <i>Haematologica</i>, 2007, 92(1):35-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/17229633/pubmed" id="17229633" target="_blank">17229633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21255716">
<a name="21255716"></a>Schulmeister L, "Extravasation Management: Clinical Update," <i>Semin Oncol Nurs</i>, 2011, 27(1):82-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/21255716/pubmed" id="21255716" target="_blank">21255716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24115731">
<a name="24115731"></a>Shukla N, Kobos R, Renaud T, et al. Phase II trial of clofarabine with topotecan, vinorelbine and thiotepa for pediatric patients with relapsed or refractory acute leukemia. <i>Pediatr Blood Cancer</i>. 2014;61:431-435.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/24115731/pubmed" id="24115731" target="_blank">24115731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smetzer.2015">
<a name="Smetzer.2015"></a>Smetzer J, Cohen M, eds. Potentially dangerous mix-up between cancer drugs. <i>ISMP Medication Safety Alert! Acute Care Edition</i>. 2015;20(20):1.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18486273">
<a name="18486273"></a>Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. <i>Lung Cancer</i>. 2009;63(1):94-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/18486273/pubmed" id="18486273" target="_blank">18486273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11099320">
<a name="11099320"></a>Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. <i>J</i>
<i>Clin Oncol</i>. 2000;18(23):3912-3917. doi:10.1200/JCO.2000.18.23.3912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/11099320/pubmed" id="11099320" target="_blank">11099320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20205253">
<a name="20205253"></a>Steinherz PG, Shukla N, Kobos R, et al. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa and vinorelbine for patients with relapsed or refractory leukemia. <i>Pediatr Blood Cancer</i>. 2010;54:687-693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/20205253/pubmed" id="20205253" target="_blank">20205253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17914077">
<a name="17914077"></a>Superfin D, Iannucci AA, Davies AM. Commentary: oncologic drugs in patients with organ dysfunction: a summary. Oncologist. 2007;12(9):1070-1083. doi:10.1634/theoncologist.12-9-1070<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/17914077/pubmed" id="17914077" target="_blank">17914077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fresenius.1">
<a name="Fresenius.1"></a>Vinorelbine Injection [product monograph]. Toronto, Ontario, Canada: Fresenius Kabi Canada Ltd; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10370781">
<a name="10370781"></a>Vogel C, O'Rourke M, Winer E, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. <i>Ann Oncol</i>. 1999;10(4):397-402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/10370781/pubmed" id="10370781" target="_blank">10370781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15972865">
<a name="15972865"></a>Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung Cancer. <i>N Engl J Med</i>. 2005;352(25):2589-2597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/15972865/pubmed" id="15972865" target="_blank">15972865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27352191">
<a name="27352191"></a>Yeo KK, Gaynon PS, Fu CH, Wayne AS, Sun W. Bortezomib, dexamethasone, mitoxantrone, and vinorelbine (BDMV): an active reinduction regimen for children with relapsed acute lymphoblastic leukemia and asparaginase intolerance. <i>J Pediatr Hematol Oncol</i>. 2016;38(5):345-349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/27352191/pubmed" id="27352191" target="_blank">27352191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11745280">
<a name="11745280"></a>Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. <i>Cancer</i>. 2001;92(9):2267-2272.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/11745280/pubmed" id="11745280" target="_blank">11745280</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 94136 Version 256.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
